Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Iida

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Sleep Medicine|December 7, 2021
Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide studyRyuji Furihata, Rei Otsuki, Naomi Hasegawa, et al.
BMC Psychiatry|June 28, 2023
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
The International Journal of Neuropsychopharmacology|June 20, 2022
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide StudyShinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|September 15, 2019
Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) surveyMin Dong, Liang-Nan Zeng, Qinge Zhang, et al.
Neuropsychopharmacology Reports|November 29, 2022
Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" projectHitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, et al.
Asian Journal of Psychiatry|January 20, 2022
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE projectKayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|July 19, 2022
Network analysis of psychiatric symptoms in schizophrenia: Findings from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP)Wen Li, Qinge Zhang, Yilang Tang, et al.
Asian Journal of Psychiatry|June 6, 2022
Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site studyHiroyuki Muraoka, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Sleep Medicine|December 7, 2021
Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide studyRyuji Furihata, Rei Otsuki, Naomi Hasegawa, et al.
BMC Psychiatry|June 28, 2023
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
The International Journal of Neuropsychopharmacology|June 20, 2022
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide StudyShinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|September 15, 2019
Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) surveyMin Dong, Liang-Nan Zeng, Qinge Zhang, et al.
Neuropsychopharmacology Reports|November 29, 2022
Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" projectHitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, et al.
Asian Journal of Psychiatry|January 20, 2022
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE projectKayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, et al.
Asian Journal of Psychiatry|July 19, 2022
Network analysis of psychiatric symptoms in schizophrenia: Findings from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics (REAP-AP)Wen Li, Qinge Zhang, Yilang Tang, et al.
Asian Journal of Psychiatry|June 6, 2022
Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site studyHiroyuki Muraoka, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.
Neuropsychopharmacology Reports|November 17, 2022
Development of an individual fitness score (IFS) based on the depression treatment guidelines of in the Japanese Society of Mood DisordersKentaro Fukumoto, Fumitoshi Kodaka, Naomi Hasegawa, et al.
Pageof 6